BIONTECH SE SPON. ADRS 1
Commented by Fabian Lorenz on July 21st, 2022 | 11:34 CEST
Buy now? BioNTech, Nordex and MAS Gold
The mood on the world's stock markets has stabilized in recent days. Hopes are alive that inflation and the US dollar have seen their highs for now. Even a soft landing of the US economy is no longer ruled out. Therefore, for example, JPMorgan and Goldman Sachs advise buying shares because, from the perspective of the US banks, the chances of a V-shaped recovery of the stock markets are increasing. That could benefit stocks that have fallen by the wayside in recent months, including BioNTech. The Wiesbaden-based Company could be in for an exciting fall. A weaker US dollar would give a boost to the gold price. Gold explorer MAS Gold should be able to profit from this. Nordex has at least full coffers after two capital increases but continues to have problems. However, Jefferies advises buying.
Read
Commented by André Will-Laudien on July 18th, 2022 | 15:04 CEST
Fall is coming: BioNTech, Defence Therapeutics, CureVac, Valneva - Which biotech stock will surge again?
The summer of rising incidences is making its way, but the public has already shelved the pandemic measures and hospitals are filling up again. Even if no one wants to talk about it anymore, the fourth wave is coming! Worldwide, the race for suitable vaccines or treatment methods continues. Medicine is still relatively helpless as far as treating severe cases is concerned, and the subject of post-COVID is considered completely unexplored. We take another critical look at the landscape of biotech stocks.
Read
Commented by Fabian Lorenz on July 13th, 2022 | 14:27 CEST
MorphoSys facing a takeover? Exciting autumn ahead for BioNTech and XPhyto
Biotech investors could be in for an exciting autumn. After some sharp price corrections, positive things are happening again in the biotech sector. For one thing, the takeover carousel. It all started in June when Pfizer announced the acquisition of migraine specialist Biohaven for USD 11.6 billion, and GlaxoSmithKline plans to swallow Sierra Oncology for around USD 1.9 billion. Recent deals include the acquisitions of ViaCyte, La Jolla Pharmaceutical and Pliant Therapeutics. MorphoSys is also a possible takeover candidate. It could be a win-win for the German biotech company if the price is attractive. Xphyto could also see at least one investment, as a market-ready product has great potential.
Read
Commented by Nico Popp on July 12th, 2022 | 14:09 CEST
Waiting is not an option! BioNTech, MAS Gold, BASF
Inflation is rising and rising. In construction, inflation has already reached almost 20%. Even in everyday life, double-digit inflation rates are not far away. At the same time, infection figures are rising, and it is still uncertain whether gas will flow through Nord Stream 1 again in the coming weeks. Given this mixed situation, many investors are asking how they should invest. Because one thing is clear: waiting is not an option - the real return on many asset classes is clearly negative. We take a look at three stocks and check their future prospects.
Read
Commented by Stefan Feulner on July 11th, 2022 | 15:33 CEST
Easing at BioNTech and BASF, and Almonty Industries with a clear signal
Concerns about the onset of a global recession are increasing dramatically, as shown by the economic data published last week. As a result, almost all asset classes corrected, and the fluctuation range increased enormously. In addition to the stock markets, which have been in a correction for months, crypto and precious metals prices also fell sharply. Even the oil price, which has been booming due to the Russian sanctions, was dragged down. At current levels, however, attractive, anti-cyclical entry opportunities are emerging.
Read
Commented by Fabian Lorenz on July 7th, 2022 | 14:33 CEST
A big surprise at BioNTech, and what are Valneva and NervGen doing?
Surprise at BioNTech: competitor CureVac sues the Mainz-based biotech company for alleged patent infringements. Specifically, the lawsuit concerns BioNTech's Corona vaccine, which is based on mRNA technology. CureVac founder Ingmar Hoerr, in turn, is considered the discoverer of this new vaccination technology. However, CureVac failed with the development of its own Corona vaccine. Valneva also had no luck with its Corona vaccine, but it seems to have an attractive product pipeline. Nevertheless, the euphoria over the entry of the US pharmaceutical group Pfizer has faded. The situation at NervGen is different: according to experts, NervGen could achieve its greatest success in decades with NVG-291 in the fight against Alzheimer's disease. Tomorrow, a capital increase is to be completed, and the share price will likely regain momentum.
Read
Commented by Stefan Feulner on July 5th, 2022 | 11:14 CEST
Strong signs at BioNTech and Defence Therapeutics, and Valneva closes the gap!
****Without question, the future belongs to biotechnology. The record-breaking development of vaccines, tests and drugs in the wake of the Corona pandemic, which broke out more than two years ago, showed how important this sector is for humanity. Biotechnology stocks are consolidating strongly despite being established as a critical future technology. The NASDAQ Biotech Index has lost about 40% since last summer, creating attractive entry opportunities for investors at a significantly reduced level.
Read
Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST
BrainChip and Palantir with strong rebound - How does BioNTech react?
The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.
Read
Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST
Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?
Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.
Read
Commented by Nico Popp on June 22nd, 2022 | 12:32 CEST
Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech
When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.
Read